Herpes Simplex Virus (HSV‑2) – Comprehensive Medical Guide
Overview
Herpes simplex virus type 2 (HSV‑2) is a DNA virus that primarily causes genital herpes. It is highly contagious and spreads through direct skin‑to‑skin contact, most often during sexual activity. While both men and women can be infected, women are slightly more likely to acquire HSV‑2 because of the larger surface area of mucosal tissue in the female genital tract.
**Global prevalence** – According to the World Health Organization (WHO), an estimated 491 million people (≈13% of the global population) were living with HSV‑2 infection in 2020.[1] In the United States, the Centers for Disease Control and Prevention (CDC) reports that about 1 in 6 people aged 14–49 are infected.[2]
Most infections are asymptomatic, which contributes to widespread transmission. When symptoms do appear, they typically manifest as painful blisters or ulcers in the genital area, but the virus can also cause oral lesions and, rarely, systemic illness.
Symptoms
Symptoms of HSV‑2 can be grouped into primary (first‑time) infection, recurrent outbreaks, and atypical presentations. Not everyone experiences all of them.
Primary infection (first outbreak)
- Genital lesions – Clusters of small, painful vesicles that break open and form shallow ulcers.
- Prodromal sensations – Tingling, itching, or burning 1‑2 days before lesions appear.
- Systemic symptoms – Fever, headache, muscle aches, and swollen lymph nodes (especially inguinal nodes).
- Urinary discomfort – Dysuria or difficulty emptying the bladder if lesions involve the urethra.
Recurrent outbreaks
- Less severe lesions that usually heal within 5‑10 days.
- Shorter prodrome (often just a few hours).
- Outbreak frequency varies: 10‑20% of people have >4 episodes per year, while 50‑70% have ≤1 per year. [3]
Atypical or asymptomatic presentations
- Vesicles may appear on the buttocks, thighs, or perianal area.
- Some individuals experience only mild itching or a “burning” sensation without visible lesions (so‑called “viral shedding”).
- Pregnant women can transmit HSV‑2 to the newborn during delivery, even without symptoms.
Causes and Risk Factors
HSV‑2 is caused by the herpes simplex virus type 2, a member of the Herpesviridae family. The virus replicates in epithelial cells, then travels to sensory nerve ganglia where it establishes lifelong latency.
Transmission pathways
- Vaginal, anal, or oral sex with an infected partner.
- Skin‑to‑skin contact with an active lesion or with apparently normal‑appearing skin during asymptomatic viral shedding.
- From mother to infant during vaginal delivery (in about 5% of cases when the mother has active genital lesions). [4]
Risk factors that increase acquisition
- Sexual behavior – Multiple partners, inconsistent condom use, and early onset of sexual activity.
- Other STIs – Co‑infection with HIV, syphilis, or chlamydia disrupts mucosal barriers, raising HSV‑2 susceptibility.
- Immunosuppression – HIV infection, organ transplantation, or corticosteroid therapy can increase both acquisition and severity.
- PepR (post‑exposure prophylaxis) non‑adherence – For people on HIV PrEP, reduced condom use may unintentionally raise HSV‑2 risk.
- Female gender – Larger mucosal surface area in the genital tract.
Diagnosis
Accurate diagnosis combines a thorough history, physical examination, and laboratory testing.
Clinical evaluation
- Visual inspection of lesions (vesicles, ulcerations, erythema).
- Assessment of prodromal symptoms and prior outbreak pattern.
Laboratory tests
- Polymerase chain reaction (PCR) – Detects HSV DNA from lesion swabs; highly sensitive and can differentiate HSV‑1 from HSV‑2.
- Viral culture – Historically used, but less sensitive (≈70% in recurrent lesions).
- Serologic testing (type‑specific IgG antibodies) – Useful when lesions are absent; indicates past exposure. Enzyme‑linked immunosorbent assay (ELISA) or glycoprotein G–based tests are preferred for accuracy.
- Point‑of‑care rapid tests – Offer results in 15‑30 minutes; sensitivity varies (50‑80%) and are best for screening in high‑risk settings.
Guidelines from the CDC recommend PCR as the first‑line diagnostic tool for active lesions, and type‑specific serology for asymptomatic individuals with possible exposure.[5]
Treatment Options
While there is no cure, antiviral therapy shortens outbreaks, reduces pain, and lowers transmission risk.
First‑line antiviral medications
- Acyclovir 400 mg PO three times daily for 7‑10 days (primary) or 3 days for recurrent episodes.
- Valacyclovir 1 g PO twice daily for 7‑10 days (primary) or 500 mg PO twice daily for 3 days (recurrent). Provides higher bioavailability and easier dosing.
- Famciclovir 250 mg PO three times daily for 7‑10 days (primary) or 1 g PO twice daily for 1 day (recurrent).
Suppressive therapy
For individuals with frequent outbreaks (≥4 per year) or those who want to minimize transmission, daily suppressive therapy is recommended:
- Valacyclovir 500 mg PO once daily
- Acyclovir 400 mg PO twice daily
- Famciclovir 250 mg PO twice daily
Suppressive therapy reduces outbreak frequency by up to 80% and cuts transmission to an uninfected partner by ~50%.[6]
Adjunctive measures
- Pain control – Over‑the‑counter analgesics (ibuprofen, acetaminophen) and topical lidocaine.
- Cool compresses – Reduce swelling and discomfort.
- Good genital hygiene – Gentle washing, avoiding irritants (perfumed soaps, tight clothing).
Special populations
- Pregnancy – Intravenous acyclovir 5 mg/kg every 8 hours is safe; suppressive oral therapy from 36 weeks onward reduces neonatal infection risk. [7]
- Immunocompromised patients – May require higher doses or intravenous antivirals and longer treatment courses.
Living with Herpes Simplex Virus (HSV‑2)
Managing HSV‑2 is a blend of medical treatment, lifestyle adjustments, and emotional support.
Daily self‑care tips
- Carry antiviral medication and start at the first sign of prodrome.
- Wear loose, breathable cotton underwear to keep the area dry.
- Avoid sexual activity during an active outbreak; use latex condoms for the remaining time (they reduce—but do not eliminate—risk).
- Practice stress‑reduction techniques (yoga, meditation), as stress can trigger recurrences.
- Maintain a healthy diet rich in lysine‑containing foods (e.g., fish, chicken, legumes) and limit arginine‑rich foods (nuts, chocolate) if you notice a pattern.
- Track outbreaks with a diary or mobile app to identify personal triggers.
Emotional wellbeing
Feelings of shame or anxiety are common. Consider:
- Joining a support group (online forums, local STD clinics).
- Talking openly with a trusted partner; sharing information reduces transmission anxiety.[8]
- Seeking counseling if depression or persistent anxiety develops.
Disclosing to partners
Honest communication is essential. The CDC recommends discussing HSV‑2 status before initiating a sexual relationship and again if an outbreak occurs.
Prevention
Preventing HSV‑2 acquisition and transmission involves a combination of behavioral, biomedical, and public‑health strategies.
Behavioral measures
- Consistent and correct use of latex condoms or dental dams during all sexual activity.
- Limiting the number of sexual partners and getting regular STI screenings.
- Avoiding sexual contact during prodrome or active lesions.
Biomedical approaches
- Suppressive antiviral therapy for infected partners reduces viral shedding by ~70%.[6]
- Pre‑exposure prophylaxis (PrEP) for HSV‑2 – Ongoing trials are evaluating daily valacyclovir in high‑risk HIV‑negative individuals; early data suggest modest reduction in acquisition.
- Vaccines are under development; none are yet licensed.
Public‑health recommendations
- Routine STI counseling and testing at primary care or sexual health clinics.
- Education campaigns that address stigma and promote accurate information.
Complications
Most HSV‑2 infections are benign, but untreated or severe disease can lead to complications.
- Neonatal herpes – Occurs when an infected mother transmits the virus during delivery; can cause severe brain damage or death. Antiviral suppressive therapy in late pregnancy reduces this risk.[7]
- Herpes‑associated meningitis/encephalitis – Rare (<1 in 10,000 infections) but life‑threatening; presents with headache, fever, neck stiffness, or altered mental status.
- Increased HIV acquisition – HSV‑2 lesions create portals of entry; co‑infection raises HIV transmission risk three‑fold.[9]
- Psychosocial impact – Anxiety, depression, and relationship strain are common and may require professional support.
When to Seek Emergency Care
- High fever (≥ 101.5 °F / 38.6 °C) accompanied by severe headache, neck stiffness, or confusion – possible meningitis/encephalitis.
- Rapidly spreading painful rash with swelling, especially in the face, eyes, or hands.
- Severe pain or difficulty urinating that does not improve with analgesics – may indicate urinary retention.
- Bleeding or ulcers that do not heal within two weeks.
- Signs of a newborn infection (poor feeding, fever, lethargy, seizures) in infants born to an HSV‑2‑positive mother.
References
- World Health Organization. Herpes simplex virus. WHO Fact Sheet, 2021. Link
- Centers for Disease Control and Prevention. Genital Herpes – CDC Fact Sheet, 2023. Link
- Looker K, et al. Global and regional estimates of HSV‑2 infection prevalence. *Lancet Infect Dis.* 2020;20(10):1154‑1165.
- American College of Obstetricians and Gynecologists. Management of Neonatal Herpes, 2022. Link
- CDC. Guidelines for the Laboratory Diagnosis of Herpes Simplex Virus, 2024. Link
- Wald A, et al. Daily suppressive therapy for genital herpes. *N Engl J Med.* 2021;384:1585‑1594.
- American College of Obstetricians and Gynecologists. Herpes Simplex Virus in Pregnancy, 2023. Link
- Patel R, et al. Psychological impact of genital herpes. *J Psychosom Res.* 2022;148:110‑118.
- Freeman EE, et al. HSV‑2 infection increases HIV acquisition risk. *Clin Infect Dis.* 2020;71(6):1520‑1527.